Tumor-associated macrophages (TAMs) are known to regulate tumor response to many anti-cancer therapies, including oncolytic virotherapy. Oncolytic virotherapy employing oncolytic paramyxoviruses, such as attenuated measles (MeV) and mumps (MuV) viruses, has demonstrated therapeutic potential against various malignancies. However, the response of TAMs to oncolytic paramyxoviruses and the consequent effect on virotherapeutic efficacy remains to be characterized. Here, we demonstrate that the presence of human monocyte-derived macrophages (MDMs), irrespective of initial polarization state, enhances the virotherapeutic effect of MeV and MuV on breast cancer cells. Notably, our finding contrasts those of several studies involving other oncolytic viruses, which suggest that TAMs negatively impact virotherapeutic efficacy by impeding virus replication and dissemination. We found that the enhanced virotherapeutic effect in the presence of MDMs was due to slightly delayed proliferation and significantly elevated cell death that was not a result of increased virus replication. Instead, we found that the enhanced virotherapeutic effect involved several macrophage-associated anti-tumor mediators, and was associated with the modulation of MDMs towards an anti-tumor phenotype. Our findings present an alternative view on the role of TAMs in oncolytic virotherapy, and highlight the immunotherapeutic potential of oncolytic paramyxoviruses; possibly contributing towards the overall efficacy of oncolytic virotherapy.
Keywords: Macrophages · Measles virus · Mumps virus · Oncolytic virotherapy · Tumor microenvironmentAdditional supporting information may be found in the online version of this article at the publisher's web-site
IntroductionSuboptimal therapeutic efficacy remains an area of concern in the development of oncolytic virotherapy. Oncolytic virotherapy employs oncotropic replication-competent viruses with mechanisms of action that extend beyond the direct cytolysis of malignant cells; encompassing the induction of anti-tumor immunity and the actions of encoded therapeutic transgenes [1]. Studies on non-transgene-encoding oncolytic viruses (OLVs) have Correspondence: Prof. Naoki Yamamoto e-mail: micny@nus.edu.sg characterized the involvement of various tumor microenvironment components including the tumor vasculature [2,3], extracellular matrix [4], and infiltrating immune cells [2,[5][6][7][8][9]. In addition, OLVs armed with tumor microenvironment-modulating therapeutic transgenes have exhibited improved preclinical efficacy [1,10]. Notably, OLV-induced anti-tumor immunity appears to be a key determinant of successful oncolytic virotherapy [10]. Therefore, tumor microenvironment constituents are significant determinants of virotherapeutic efficacy.A major cellular constituent of tumor microenvironments, found to counteract or support many cancer therapies, are macrophages [11]. In many cancers, tumor-associated macrophage (TAM) density strongly correlates with poor [33]. However, the influence of TAMs on the virotherape...